Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 7/20 | 0.48 |
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.47 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23700411 | 1.00 | OPRM1 (0.49) | OPRM1OPRK1EPHA2NMUR2NMUR1 | |
| SCHEMBL23700407 | 1.00 | OPRM1 (0.49) | OPRM1OPRK1EPHA2NMUR2NMUR1 | |
| SCHEMBL23710062 | 0.94 | OPRM1 (0.45) | OPRM1OPRK1EPHA2NMUR2NMUR1 | |
| SCHEMBL23700293 | 0.91 | EPHA2 (0.55) | OPRM1OPRK1EPHA2NMUR2NMUR1 | |
| SCHEMBL23700295 | 0.91 | EPHA2 (0.55) | OPRM1OPRK1EPHA2NMUR2NMUR1 | |
| SCHEMBL23700292 | 0.91 | EPHA2 (0.55) | OPRM1OPRK1EPHA2NMUR2NMUR1 | |
| SCHEMBL23710183 | 0.91 | EPHA2 (0.55) | OPRM1OPRK1EPHA2NMUR2NMUR1 | |
| SCHEMBL23700285 | 0.88 | NMUR2 (0.53) | OPRM1OPRK1EPHA2NMUR2NMUR1 | |
| SCHEMBL23700287 | 0.88 | NMUR2 (0.53) | OPRM1OPRK1EPHA2NMUR2NMUR1 | |
| SCHEMBL23710077 | 0.88 | NMUR2 (0.53) | OPRM1OPRK1EPHA2NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238225-A1 | PEPTIDOMIMETIC INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238225-A1 | PEPTIDOMIMETIC INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) | PIN1, PPIA, PPIE | OPRM1 3964/4885OPRK1 4201/4885EPHA2 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.